The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 10, 2015, Pages 1192-1199

  Dumitrescu, G ^a,b   Amiot, A ^c   Seksik, P ^d   Baudry, C ^e   Stefanescu, C ^a   Gagniere, C ^c   Allez, M ^e   Cosnes, J ^d   Bouhnik, Y ^a  

^a BEAUJON HOSPITAL   (France)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID; TACROLIMUS; IMMUNOLOGIC FACTOR;

ADD ON THERAPY; ADULT; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; REMISSION; RETROSPECTIVE STUDY; REVIEW; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84943658454     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13393     Document Type: Review

References (30)

1. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
2. Danese S, Colombel JF, Peyrin-Biroulet L, et al,. Review article: the role of anti-TNF in the management of ulcerative colitis-past, present and future. Aliment Pharmacol Ther 2013; 37: 855-66.
3. Ferrante M, Vermeire S, Fidder H, et al,. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008; 2: 219-25.
4. Teisner AS, Ainsworth MA, Brynskov J,. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience. Scand J Gastroenterol 2010; 45: 1457-63.
5. Allez M, Karmiris K, Louis E, et al,. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355-66.
6. Oussalah A, Evesque L, Laharie D, et al,. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010; 105: 2617-25.
7. Seow CH, Newman A, Irwin SP, et al,. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
8. Katz L, Gisbert JP, Manoogian B, et al,. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012; 18: 2026-33.
9. Dignass A, Lindsay JO, Sturm A, et al,. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030.
10. Panaccione R, Ghosh S, Middleton S, et al,. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: e3.
11. Colombel JF, Sandborn WJ, Reinisch W, et al,. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
12. Sokol H, Seksik P, Carrat F, et al,. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 1363-8.
13. Ben-Horin S, Waterman M, Kopylov U, et al,. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 444-7.
14. Stange EF, Travis SP, Vermeire S, et al,. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008; 2: 1-23.
15. Cosnes J SP,. Computer database for patients with IBD. In:, T.M. Bayless, S.B. Hanauer, eds. Advanced Therapy in Inflammatory Bowel Disease. Shelton, CT: People's Medical Publishing House, 2011; 117-24.
16. Satsangi J, Silverberg MS, Vermeire S, et al,. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
17. Sandborn WJ, Colombel JF, D'Haens G, et al,. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-13.
18. Stidham RW, Lee TC, Higgins PD, et al,. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2014; 39: 660-71.
19. Afif W, Leighton JA, Hanauer SB, et al,. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009; 15: 1302-7.
20. Mortensen C, Caspersen S, Christensen, NL, et al,. Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. J Crohns Colitis 2011; 5: 28-33.
21. Waters H, Vanderpoel J, McKenzie S, et al,. Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review. J Med Econ 2011; 14: 397-402.
22. Rostholder E, Ahmed A, Cheifetz AS, et al,. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther 2012; 35: 562-7.
23. Cesarini M, Katsanos K, Papamichael K, et al,. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis 2014; 46: 135-9.
24. Lichtiger S, Present DH, Kornbluth A, et al,. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5.
25. Chowers Y, Sturm A, Sans M, et al,. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis 2010; 4: 367-76.
26. Pariente B, Pineton de Chambrun G, Krzysiek R, et al,. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 1199-206.
27. Sandborn WJ, Rutgeerts P, Feagan BG, et al,. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-60; quiz 1520.
28. Sokol H, Beaugerie L,. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009; 58: 1427-36.
29. Lichtenstein GR, Diamond RH, Wagner CL, et al,. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-26.
30. Turner D, Griffiths AM, Veerman G, et al,. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol 2013; 11: 1460-5.